Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus Pfizer Inc. has announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM). Moving …
Pfizer’s GLP-1-RA Program: Obesity and Type 2 Diabetes Update Read More »